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What is the central question of this study? 
It is suggested that remote ischemic preconditioning (RIPC) may offer protection against 
ischemia-reperfusion injuries, yet the utility of RIPC in high-altitude settings remains unclear.  
 
What are the main findings and its importance? 
We found that RIPC offers no vascular protection relative to pulmonary artery pressure or 
peripheral endothelial function during acute, normobaric hypoxia, and at high-altitude in young, 
healthy adults. However, peripheral chemosensitivity was heightened 24 hours following RIPC 
at high altitude.  
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ABSTRACT 
Application of repeated short duration bouts of ischemia to the limbs, termed remote ischemic 
preconditioning (RIPC), is a novel technique that may have protective effects on vascular 
function during hypoxic exposures. In separate parallel-design studies, at sea-level (SL; n=16), 
and after 8-12 days at high-altitude (HA; n=12; White Mountain, 3800m), participants underwent 
either a sham protocol or one session of 4x5 minutes of dual-thigh cuff occlusion with 5-minutes 
recovery. Brachial artery flow-mediated dilation (FMD; ultrasound), pulmonary artery systolic 
pressure (PASP; echocardiography), and internal carotid artery flow (ICA; ultrasound) were 
measured at SL in normoxia and isocapnic hypoxia [end-tidal PO₂ (PETO₂) maintained to 
50mmHg], and during normal breathing at HA. The hypoxic ventilatory response (HVR) was 
measured at each location. All measures at SL and HA were obtained at baseline (BL), 1 hour, 
24 hours, and 48 hours post-RIPC or sham. At SL, RIPC produced no changes in FMD, PASP, 
ICA flow, end-tidal gases or HVR in normoxia or hypoxia. At HA, although HVR increased 24 
hours post RIPC compared to BL (2.05±1.4 vs. 3.21±1.2 L·min-1·%SaO2-1, p<0.01), there were 
no significant differences in FMD, PASP, ICA flow, resting end-tidal gases. Accordingly, a 
single session of RIPC is insufficient to evoke changes in peripheral, pulmonary, and cerebral 
vascular function in healthy adults. Although chemosensitivity may increase following RIPC at 
HA, this did not confer any vascular changes. The utility of a single RIPC session seems 
unremarkable during acute and chronic hypoxia. 
 
Key Words: Remote ischemic preconditioning; High-altitude; Hypoxia; Pulmonary artery 
pressure; Vascular function; Cerebral blood flow; Chemosensitivity  
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INTRODUCTION  
 
Remote ischemic preconditioning (RIPC) is a non-invasive procedure that has substantial effects 
on protecting various organs in the body against ischemia-related injuries. In humans and animal 
models alike, cyclic 5-10 minute periods of occlusion and reperfusion of blood flow through a 
limb, with total treatment times ranging from 40-60 minutes produces significant protection 
against ischemia in the heart (Murry et al., 1986), lungs (Kinoshita, 2015), kidneys (Wever et al., 
2011), liver (Yan et al., 2015)  and brain (Koch et al., 2011). The exact mechanisms responsible 
for these effects remain unclear, but are likely a result of activation of various anti-inflammatory 
and anti-oxidative pathways [for review see: (Koch et al., 2014)].  
 
Recent findings suggest that RIPC may also play a role in protection from hypoxic and altitude-
related injuries (Berger et al., 2015b).  For example, in athletes, one 4x5 minute RIPC treatment 
in the lower limb attenuates the rise in pulmonary artery systolic pressure (PASP) normally seen 
after 90 minutes of  normobaric hypoxia (Foster et al., 2011), and 5 days of consecutive 
treatment has shown similar pulmonary vascular protective effects when conducted prior to 
travel to high altitude (Foster et al., 2014). Together, these findings suggest that preconditioning 
may offer a degree of protection against the onset of high altitude pulmonary edema. In addition, 
RIPC has also been linked to reduced oxidative stress and lower symptoms of acute mountain 
sickness after acute exposure to normobaric hypoxia (Berger et al., 2015a); however, these 
findings were only observed transiently (0-12hours). After a brief period of no observable 
protection, a second delayed window of protection appears after ~18-20 hours and lasts for 1-2 
days (Miguel, 2004; Koch et al., 2014). While clinical outcomes as a result of RIPC seem 
promising (Thielmann et al., 2013), only a very limited number of studies have investigated 
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RIPC and potential further protection against hypoxia (Foster et al., 2011, 2014; Berger et al., 
2015a). 
 
High-altitude represents an experimental model that allows for the study of hypoxic adaptation in 
healthy humans. In addition to marked changes in PASP and cerebral blood flow (Stembridge et 
al., 2014; Willie et al., 2014), ascent to high altitude is typically associated with a decline in 
vascular function, as demonstrated by impaired endothelial-dependent flow-mediated dilation 
(FMD) (Lewis et al., 2014; Bakker et al., 2015) and endothelial-independent dilation (Lewis et 
al., 2014). Such impairment in vascular function may further compromise the body’s ability to 
tolerate the various stresses associated with hypoxia. Increased sympathetic nerve activity (SNA) 
and disturbed blood flow may contribute to the hypoxia-associated reduction in FMD (Lewis et 
al., 2014; Tremblay et al., 2016). Additionally, the impairment may be attributed to an increase 
in oxidative stress, which may interfere with the intracellular signalling processes required for 
smooth muscle relaxation (Munzel et al., 2004). Remote ischemic preconditioning reduces 
oxidative stress after ischemic injuries (Chen et al., 2015), and these same activated pathways 
may also attenuate the decline in vascular function at high altitude. Furthermore, RIPC has been 
demonstrated to preserve FMD immediately after strenuous exercise (Bailey et al., 2012), a 
period that is normally associated with elevations in SNA and a temporary impairment in 
vascular function (Atkinson et al., 2015; Tymko et al., 2016b). 
 
Therefore, the primary aim of this study was to explore the potential protective benefits of one 
single session of RIPC (4 x 5 min) on integrative vascular function during both acute and chronic 
exposure to hypoxia. The previously observed reduction in PASP and improved haemoglobin 
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saturation at altitude in response to RIPC (Foster et al., 2014) could potentially be explained by a 
larger hypoxic ventilatory response (HVR), although this possibility has not yet been 
investigated. Therefore, a secondary objective of this study was to examine if RIPC evokes any 
changes in peripheral chemosensitivity to hypoxia. Finally, based on reports that RIPC offers 
two distinct protective windows (Koch et al., 2014) - from 0-12 hours, and again from 18-72 
hours - measurements were repeated immediately (1 hour), 24 hours and 48 hours after the initial 
RIPC treatment. We hypothesized that RIPC of the lower limbs would reduce the pulmonary 
artery pressure increase normally observed in hypoxia (Swenson, 2013), as well as attenuate the 
hypoxic impairment in FMD (Lewis et al., 2014). We also reasoned that the RIPC intervention 
would increase the HVR, thereby explaining the previously reported elevations in peripheral 
oxygen saturation (Foster et al., 2014). Given that >80 million of people live above 2500 meters 
and many more travel to altitude per year, with 10-85% of these getting some form of altitude 
illness (Hackett et al., 1976; Maggiorini et al., 1990), determining the impact of RIPC may 
provide a simple and inexpensive strategy to alleviate high altitude related illnesses.  
MATERIALS AND METHODS 
This experiment was conducted in two separate parts, with one protocol taking place near sea-
level (Kelowna, Canada; 344 m), and the second protocol starting after 8-10 days at high altitude 
(Barcroft Station, White Mountain, California; 3800 m). This study was a part of a series of 
experiments that took place over the course of a two-week research expedition to Barcroft 
Station, starting with rapid ascent to high altitude (3800 m, <6-hour drive) on day one. There was 
no overlap between participation in this study and participation in other investigations relative to 
carry over effects of drugs and/or exercise, and the questions addressed in this paper are dealt 
with exclusively within this study alone. During the entirety of their stay at Barcroft Station, 
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participants had access to regular meals and fluids ad lib. All participants abstained from 
vigorous exercise, caffeine and alcohol for 12 hours prior to testing, and were asked to consume 
a light snack two hours before coming to the laboratory.  
 
Participants: 
All participants were free of overt cardiovascular, respiratory and cerebrovascular disease, were 
non-diabetic, and not taking any prescription medications (other than oral contraceptives, n=2) at 
the time of their participation, as determined by a screening questionnaire. Each subject provided 
written informed consent prior to arrival at the lab for familiarization. Participants were different 
for the SL and HA components of the study, with select characteristics described below. This 
study was approved by the University of British Columbia Clinical Research Ethics board and 
conformed to standards set by the Declaration of Helsinki, except for registration in a database, 
and the Canadian Government Tri-Council Policy Statement for Integrity in Research.  
 
Experimental Design: 
Part 1: Sea Level (Acute hypoxia) 
Participants came into the lab on three consecutive days, where the protocol was performed on 
the first day (Baseline) and then repeated again at three time points: 1 hour (Day 1), 24 hours 
(Day 2), and 48 hours (Day 3). The testing protocol is depicted in Figure 1. Immediately after 
BL, subjects were randomly allocated into either dual-thigh RIPC or a Sham treatment, both of 
which are described below.  
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For each session (BL, 1 hour, 24 hours, 48 hours), subjects lay supine while being instrumented 
for the tests (described further in “Experimental Measurements”). After 20 minutes of supine rest 
normoxic echocardiographic images were obtained. Next, a baseline FMD test of the brachial 
artery was performed, followed by 5 minutes of rest, where baseline VE (ventilation), SpO2% 
(peripheral oxygen saturation), BP (blood pressure) and MCAv (middle cerebral artery blood 
velocity) were collected. Subjects breathed on an end-tidal air forcing system (described below) 
where the end-tidal partial pressures of O₂ and CO₂ (PETO2 and PETCO2, respectively) were 
clamped to match previously measured room air values. Once steady state was achieved, the 
ultrasonographer began scanning the internal carotid artery (ICA) and obtained at least one 
minute of satisfactory recordings before the isocapnic hypoxia stage. The sonographer held the 
image of the ICA in place while PETO2 was subsequently and rapidly dropped to 50 mmHg, 
while PETCO2 was maintained at room-air values. From the establishment of steady state, ICA 
images were then obtained continuously over the first 10 minutes of hypoxia. Starting at minute 
15, a second brachial artery FMD was performed, followed by echocardiographic image 
acquisition (for PASP) at minute 30. Therefore, room air and hypoxia measures were collected in 
every visit. The level of hypoxia (PETO2 = 50 mmHg) was selected in order to provide an 
approximated, comparable hypoxic stimulus to that experienced during the subsequent HA 
component of the study at Barcroft station (Severinghaus et al., 1966). 
 
Part 2. High Altitude (Chronic hypoxia) 
A similar time profile was used to the sea-level study. Subjects were tested on three consecutive 
days, between the 8
th
 and 12
th
 day of continuous residence at the Barcroft Station (3800m), 
where the protocol was performed on the first day (BL), and then repeated at the three time 
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points: 1 hour (Day 1), 24 hours (Day 2), and 48 hours (Day 3). The experimental protocol is 
depicted in Figure 2.  Immediately after BL, subjects were randomly allocated to either dual 
thigh- RIPC or a sham treatment which acted as time-based control.  Consequent to our limited 
participant pool at HA, eight participants were selected to receive RIPC in order to more clearly 
identify any physiological changes after treatment, and the remaining four served as a time-
control subset. Cardiorespiratory changes throughout acclimatization have been well-
documented, and after the first week, day-to-day changes in HR, VE, and SPO₂ are minimal 
(Swenson & Bärtsch, 2014). 
While resting in the supine position, subjects were instrumented for testing. After 20 minutes of 
rest, echocardiographic images (for PASP) were acquired, followed by a FMD test of the 
brachial artery. Baseline ventilatory measurements were then taken followed by end-tidal 
forcing, clamping PETO2 and PETCO2 to BL values. ICA velocity and diameter were measured 
for at least 1 minute, followed by a subsequent isocapnic drop in PETO2 to 45 mmHg.  This level 
of hypoxia was selected in order to provide a significant hypoxic stimulus beyond what was 
already being experienced by the participants at Barcroft station.  Once steady state was 
achieved, ICA measures were taken for 10 minutes, along with measures of VE, SpO2%, BP and 
MCAv. 
 
Remote Ischemic Preconditioning: 
Participants were seated in a chair with blood pressure cuffs placed around both legs at mid-thigh 
level. At sea level, an automated rapid inflation system was used to quickly inflate the cuffs to 
225 mmHg, whereas at high altitude a manual hand pump was used to increase the cuff pressure. 
The cuffs remained inflated for 5 minutes, followed by a 5 minute period of deflation allowing 
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for reperfusion of blood flow to the limb. This process was repeated 4 times, for a total treatment 
time of 40 minutes (Foster et al., 2014). In the time control and sham conditions, the cuffs were 
only inflated to <20mmHg. We chose this method of dual-thigh occlusion in order to simulate an 
easily-reproducible treatment that could be applied on short notice in remote locations, with 
minimal time and equipment. In practice, it could be used in situations where rapid ascent to 
altitude is required with short notice, or as a treatment to mitigate risk in those already in a 
hypoxic setting.  
 
Experimental Measurements: 
 
Cardiorespiratory 
In both studies at sea level and high altitude, cardiorespiratory variables were sampled 
continuously throughout the protocol at 1KHz via an analogue-to-digital converter (Powerlab, 
16/30; ADInstruments, Colorado Springs, CO).  A 3-lead electrocardiogram (ADI bioamp 
ML132) was used to measure heart rate (HR), and beat-to-beat blood pressure was recorded by 
finger photoplethysmography (Finometer PRO, Finapres Medical Systems, Amsterdam, 
Netherlands). The Finometer reconstructed brachial waveform was used for calculation of mean 
arterial pressure (MAP) after back-calibrating to the average of three automated brachial blood 
pressure cuff measurements made at rest (Tango+; Suntech, Morrisville, NC). Respiratory flow 
and minute ventilation (VE) was measured by a pneumotachograph (HR800L, HansRudolph, 
Shawnee, KS) connected in series to a bacteriological filter, and a calibrated gas analyzer 
(ML206, ADInstruments) was used to record the partial pressure of both end-tidal CO₂ and end-
tidal O₂, sampled at the level of the mouth. Arterial O₂ saturation was measured continually 
using pulse oximetry (ADInstruments). All measures, unless otherwise stated, are reported as 
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averages over 1-minute bins. In the acute hypoxia protocol, hypoxic cardio-respiratory 
measurements are taken between minutes 25-30 of isocapnic hypoxia.  In the chronic hypoxia 
protocol, hypoxic measurements are taken between minutes 9-10 of isocapnic hypoxia. These 
time-frames were chosen as the most suitable representations of steady-state for each test. 
 
End-tidal forcing 
A dynamic end-tidal forcing system was used to control PETCO2 and PETO2 during the normoxic 
and isocapnic hypoxic periods of the protocols. This system has previously been described in 
detail (Tymko et al., 2015, 2016a), and is able to effectively control end-tidal gases independent 
of ventilation at low and high altitudes. PETCO2 was kept constant at resting room air values 
throughout the two protocols, while PETO2 was rapidly dropped during the room-air to hypoxia 
transition until steady-state was achieved; this was determined as at least three consecutive 
breaths within 1 mmHg of the desired target.  
 
Peripheral chemosensitivity 
Following the onset of hypoxia, ventilatory and end-tidal data were averaged into 15-second 
bins. The HVR was calculated using the peak 15-second bin of ventilation following the 
transition from normoxia to isocapnic hypoxia on the end-tidal forcing system (described above). 
This peak 15s bin was compared to a 30s bin of data collected immediately prior to the hypoxic 
drop, and the HVR was thus calculated using the formula: HVR = Δ VE / Δ ScO2% , with ScO2 
(calculated oxygen saturation) calculated from the end-tidal O₂ trace using the equation 
described by Severinghaus, (Severinghaus, 1979).  We used this equation to calculate saturation 
over pulse oximetry in order to more accurately reflect the timing of changes in blood 
oxygenation.    
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Flow-mediated dilation 
Reactive hyperemia flow-mediated dilation was performed according to internationally-
recognized guidelines (Thijssen et al., 2011). Participants were lying supine with their left arm 
extended in a fixed position ~80 degrees perpendicular from their body. All measurements were 
taken after at least 20 minutes of supine rest in a quiet, dark room. Brachial artery image 
acquisition was obtained using a 10 MHz multifrequency linear array probe attached to a high-
resolution ultrasound machine (15L4, Terason t3200, Burlington, MA, USA). All images were 
acquired by the same experienced ultrasonographer (JCT), whom has a between-day coefficient 
of variation in FMD of 8.3 ± 2.1% (n=10, unpublished data). Following optimal image 
acquisition, and one-minute of baseline recordings, the forearm was occluded by inflating the 
cuff to 220-250 mmHg for five-minutes. Recordings of diameter and velocity continued 30-
seconds prior to cuff deflation and continuously for three-minutes thereafter. Video recordings 
were anonymized and stored for later offline analysis using specialized edge-detection software 
(Woodman et al., 2001; Thijssen et al., 2011). Flow-mediated dilation was calculated as the peak 
increase in diameter following cuff deflation. The FMD stimulus was calculated as the shear rate 
area under the curve (SRAUC) from the onset of reactive hyperemia to FMD (Pyke & 
Tschakovsky, 2007). 
 
Measurement of extra- and intra-cranial blood flow 
A 10MHz multi-frequency linear array duplex ultrasound (Terason T3200, Teratech, Burlington, 
MA) was used to measure blood velocity and diameter of the internal carotid artery (ICA). These 
recordings were acquired using simultaneous B-mode imaging (diameter) and pulse-wave mode 
(velocity). In order to eliminate recordings of turbulent and retrograde flow, measurements were 
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taken at least 1.5cm distal to the common carotid bifurcation. To avoid any artificial changes in 
arterial wall brightness/thickness, there was no alteration in B-mode gain upon acquisition of the 
first ultrasound image. Data were anonymized and later analysed offline using the same edge-
detection software as described above, and values are reported as an average over a minimum of 
12 consecutive cardiac cycles. Flow-reactivity was calculated using a 30-second bin 
encompassing the peak response to hypoxia. 
Blood velocity through the left middle vertebral artery (MCAv) was recorded using a 2MHz 
transcranial Doppler ultrasound (Spencer Technologies, Seattle, WA). A specialized headband 
(model M600 bilateral head frame, Spencer Technologies) was used to secure the probe in place. 
Insonation was achieved through the trans-temporal window using previously described location 
and standardization techniques (Willie et al., 2011), and data are reported as the average across 
selected 30-second bins during each stage.  
 
Echocardiography 
All echocardiographic images were obtained by the same experienced sonographer on a 
commercially available ultrasound machine (Vivid Q (Sea-Level) / E9 (High Altitude), GE, 
Fairfield, CT). M5-S 1.5-4.6 MHz and 4V 1.5-40 MHz transducers were used to collect 
echocardiographic images, which were saved for offline analysis (Echopac v.113, GE, Fairfield, 
CT). Subjects lay in the supine left lateral decubitus position.  The modified Bernoulli equation 
was used to calculate pulmonary artery systolic pressure, where PASP = 4V
2
 + 5mmHg, where V 
equals the peak tricuspid regurgitation velocity and 5 mmHg was added for right atrial pressure 
where the inferior vena cava collapsed under inspiration (Lawrence G Rudski MD et al., 2010). 
Measures of PASP are reported using the average of at least three cardiac cycles.  
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Statistical Analysis: 
Based upon previous studies investigating FMD and PASP during hypoxia, sample sizes of 9-12 
(Foster et al., 2014; Jones et al., 2014b; Lewis et al., 2014) were able to show significant 
changes. We therefore attempted to have >10 participants in each group; however, the time 
allocated and subject availability for this study only allowed us to have 8 participants in each 
group at SL, and a small subset of four time-control participants in the HA trial. For example, 
during isocapnic hypoxia at SL, if we were to assume a PASP of 30 mmHg, and wished to detect 
a 10% reduction following RIPC, with a standard deviation of the differences of 2.5 mmHg, a 
power of 0.8 and alpha of 0.05, we would need 10 participants. Results from this study must 
therefore be treated as preliminary, rather than confirmatory and further studies employing larger 
sample sizes are needed.  
In Study 1 (Acute hypoxia), a two-way repeated measures ANOVA was used for the 
cardiovascular measures in each treatment group (Factors: Time & O₂). In addition, a two-way 
repeated measures ANOVA (Factors: Time & Treatment) was used to identify differences in the 
HVR and ICA reactivity, as well as the change from normoxia to hypoxia for FMD and PASP. 
In study 2 (Chronic hypoxia), independent one-way ANOVAs were used on both the RIPC 
group and the time-control group (Factor: Time). Upon detection of significant main effects, 
pairwise comparisons were made using Dunnett’s t-tests.  While it has recently become 
convention to allometrically scale FMD changes (Atkinson & Batterham, 2013) and scale for 
SRAUC as a covariates (Atkinson & Batterham, 2015) baseline diameter and SRAUC did not 
differ between groups in this study, and were therefore not corrected for. Furthermore, normality 
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of all main outcome variables (FMD, PASP, qICA, VE, and HVR) was confirmed using a 
Shapiro-Wilk test.  All data were analysed using SPSS (version 24, IBM, Surrey, UK). Results 
are reported as mean ± standard deviation unless otherwise indicated. Statistical significance was 
defined as P<0.05. 
 
RESULTS:  
Part 1. Sea level (acute hypoxia) 
Cardiovascular responses 
Table 2 presents cardiovascular and respiratory variables during baseline and during isocapnic 
hypoxia (PETO₂ clamped to 50 mmHg). There were no significant differences in the magnitudes 
of responses to hypoxia in HR (RIPC: P=0.91; Sham: P=0.91), MAP (RIPC: P=0.51, Sham: 
P=0.37), or SpO₂ (RIPC: P=0.84, Sham: P=0.98) at any time point in either the RIPC or Sham 
condition.   
Pulmonary artery pressures 
Pulmonary pressures during normoxia and hypoxia are presented in Table 2. One subject was 
excluded from each group due to a lack of suitable echocardiographic images for measuring 
tricuspid regurgitation; thus, statistical analyses was based on seven participants in each group. 
While hypoxia consistently increased PASP during each trial (P<0.01 for both RIPC and Sham), 
the magnitude of this rise did not differ between trials (Figure 3, P=0.60).  
Flow-mediated dilation 
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Brachial artery flow-mediated dilation (%) responses during normoxia and hypoxia are shown in 
Table 2. There were no differences in baseline diameter (RIPC: P=0.67, Sham: P=0.83) or 
SRAUC (RIPC: P=0.40, Sham: P=0.99), and subsequently no changes in FMD response at any 
time in either condition. The FMD (% dilation) is presented in Table 2.  
ICA flow and intra-cranial velocity 
Isocapnic hypoxia resulted in a comparable increase in blood flow through the ICA (P<0.01 for 
both RIPC & Sham) and blood velocity in the MCA (P<0.01 for both RIPC & Sham) in both 
conditions; although neither response differed between RIPC and Sham at any point through the 
protocol (Table 2 for MCA & Figure 3 for ICA).  
Ventilation 
Ventilation was elevated during hypoxia (P<0.01 for both RIPC and Sham); however there were 
no differences in ventilation across any of the testing times (RIPC: P=0.58, Sham: P=0.89, see 
Table 2). The HVR (Figure 3) was also unaffected by either RIPC or sham treatment (P=0.45).  
Part 2. Chronic hypoxia (high altitude) 
Cardiovascular responses 
Table 3 presents selected resting cardiorespiratory variables after 8-12 days at high altitude, 
while breathing room air, as well as during isocapnic hypoxia. There were no significant changes 
within each condition (normoxia vs. hypoxia) in HR, MAP, or SPO₂ in either the RIPC or the 
Sham group (P>0.05 for all). 
Pulmonary artery pressures 
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Reliable echocardiographic images were obtained from 7 participants from the RIPC group and 4 
from the time control group. PASP (Figure 4) was unchanged from baseline after treatment in 
either group (RIPC, P = 0.64 vs. time-control, P=0.88). 
Flow-mediated dilation 
FMD of the brachial artery did not differ from baseline at any point after RIPC (P=0.89) or after 
time-control (P=0.41) (Figure 4). There were no significant differences in baseline diameter or 
SRAUC in either group (P>0.05 for all).  
ICA flow and intra-cranial velocity 
Blood flow through the ICA and velocity in the MCA both increased upon the transition from 
room air to isocapnic hypoxia (P<0.05 for both, see Table 3), although the magnitude of this 
increase did not change after either treatment (RIPC, P=0.51 and time-control, P=0.39). 
Ventilation 
Resting room air ventilation was unaffected by time in either treatment group; however, the 
hypoxic ventilatory response was higher than baseline after 24 hours treatment with RIPC. For 
example, HVR at baseline was 2.05±1.4 L·min/% SaO2, compared to 1 hour (2.44±1.3, p=0.80), 
24 hours (3.21±1.2, p=0.04), and 48 hours (2.79±1.5, p=0.21) post RIPC (Figure 5). This 
increase was driven by an elevation in VE peak (P=0.02) as well VE average (P=0.03) during 
hypoxia, 24 hours after RIPC treatment (Table 3). 
 
DISCUSSION 
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The aim of this study was to explore the potential protective effects of a single session of 4x5 
minutes of RIPC on the peripheral, cerebral, and pulmonary vasculature during exposures to 
acute and chronic hypoxia. By using tightly controlled hypoxic episodes within the laboratory, as 
well prolonged high altitude exposure in the field, we were able to test early and late protective 
windows of RIPC in acute and chronic hypoxic models. We hypothesized that our method of 
RIPC would induce prophylactic vascular benefits during exposure to acute hypoxia, as well as 
therapeutic benefits during chronic hypoxia. Contrary to our hypotheses, we did not observe any 
discernable benefits in the form of reduced PASP, improved peripheral vascular function (i.e., 
FMD), or alterations in cerebral perfusion or cerebrovascular reactivity to hypoxia. We do, 
however, report an increase in the isocapnic HVR in the late protective window (24 hours) after 
RIPC treatment at high altitude (3800 m). Although hypoxic chemosensitivity may increase 
following RIPC at HA, the absence of any accompanying benefits on resting oxygenation or the 
vasculature suggests that the utility of a single RIPC session seems unremarkable during acute 
and chronic hypoxia.  
Experimental Paradigms of RIPC 
Previous research investigating the utility of RIPC has been largely focused on clinical 
populations with the goal of improving outcomes after stroke (Dave et al., 2006; Ren et al., 
2008), myocardial infarction (Gho et al., 1996; Costa et al., 2013; Man et al., 2017), and a 
number of  ischemia related injuries [reviewed in: (Tapuria et al., 2008)]. RIPC appears to 
reduce biomarkers of tissue and neuronal damage after numerous surgical interventions 
[reviewed in: (Candilio et al., 2012)]; however, two recent large scale clinical trials (with 
concurrent propofol use) have failed to show an improvement in clinical outcomes when using 
RIPC prior to coronary artery bypass grafting (Hausenloy et al., 2015; Meybohm et al., 2015).   
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Despite extensive research into clinical utility, very little research has investigated whether RIPC 
elicits vascular benefits to those exposed to hypoxia, and if a minimum stimulus is required to 
elicit any of the potential benefits. For example, RIPC can be structured a number of different 
ways, with ischemic episodes ranging from 4-10 minutes, repeated 3-6 times within a treatment, 
and the volume of total treatments ranging from one or two days, to weeks/months of 
consecutive daily treatment (Eisen et al., 2004; Meng et al., 2012). We sought to pursue a 
simple, conservative, and potentially practical form of treatment, using 4 consecutive 5-minute 
periods of dual-thigh cuff occlusion, interspersed with 5 minutes of reperfusion, for one single 
forty-minute session. This approach was chosen as it is logistically simple, and would be easy to 
perform as a field tool in normal trekking circumstances. We took repeated measurements at 3 
separate points after the treatment to evaluate differences in previously established early (1 hour-
16 hours) and late (18 hours – 2-3 days) protective windows (Koch et al., 2014). While the 
protective effects of RIPC have commonly been attributed to the upregulation of anti-oxidative 
and anti-inflammatory pathways, the exact pathways being utilized seem to vary based on the 
target organ, and the mechanisms of activation are still unclear. Further, how these pathways 
translate into physiological changes is relatively unknown. 
RIPC and peripheral vascular function 
In humans, long-term RIPC (daily, 1 month) has been associated with improvements in resting 
endothelial function (Kimura et al., 2007). This is likely due to RIPC-triggered signalling for the 
upregulation of the NO system (Gattullo et al., 1999; Kimura et al., 2007; Arroyo-Martínez et 
al., 2016) as well as the release of vasoactive molecules such as adenosine and bradykinin (Lim 
& Hausenloy, 2012), which may trigger increases in reactivity of the endothelial lining.  
Furthermore, recent research suggests that RIPC treatment may reduce sympathetic tone 
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(Lambert et al., 2016), which would likely alter reactivity of the peripheral arteries to changes in 
shear stress. Improvements in resting FMD in healthy subjects have also been reported after 7 
consecutive days of RIPC treatments (Jones et al., 2014a), and it has been demonstrated that one 
session of RIPC offers protection against ischemia-reperfusion injury-induced (Liu et al., 2015), 
and exercise-induced (Bailey et al., 2012) impairments in FMD. However, in this latter study, 
and consistent with our findings, it was reported that resting FMD immediately after one 
treatment was unchanged. Our findings suggest that baseline and hypoxic FMD responses are 
unaffected by single-session RIPC treatment, although we also report no significant reduction in 
FMD upon the acute transition from normoxia to hypoxia. Two probable causes may contribute 
to this finding: the duration or level of hypoxia was too small to elicit a reduction in FMD 
(measured after 15 minutes in acute hypoxia); or, the magnitude of reduction in FMD was too 
small to identify with our sample size. There is emerging evidence that impairment in FMD is 
not a uniform response to hypoxia and may depend on severity, duration, concomitant exercise 
(Lewis et al., 2014; Tremblay et al., 2016; Tymko et al., 2016b), or the presence of 
cardiovascular risk factors (Frøbert et al., 2008). In the present study, failure to alter FMD with 
RIPC could subsequently be explained by the lack of a meaningful vascular impairment in our 
model of hypoxia.  
 
RIPC and pulmonary vascular tone 
It has been previously reported that a single session of RIPC prior to breathing a hypoxic gas 
mixture for 90 minutes blunts the rise in PASP (Foster et al., 2011). Furthermore, after pre-
treatment with 5 consecutive days of RIPC prior to rapid ascent to high altitude (followed by an 
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exercise challenge), the rise in PASP was also mitigated (Foster et al., 2014). Mechanisms for 
this attenuation of hypoxic pulmonary vasoconstriction remain speculative and are poorly 
understood. During the chronic hypoxia (HA) component of our study, the rise in PASP could be 
at least partially attributed to a degree of pulmonary vascular remodelling, a complex process 
with proliferative and inflammatory components (Stenmark et al., 2006) that may be affected by 
RIPC, however the magnitude and time course of remodelling with hypoxia is still unclear. 
Results from our study suggest there is no change in the amplitude of the PASP response to 
hypoxia after RIPC in either acute or chronic hypoxia; however, our measures were taken only 
30 minutes into the acute hypoxic challenge at point where PASP is still rising (Dorrington et al., 
1997). Furthermore we used a single session versus a 5-day repeated protocol, which may lead to 
dose dependent effects. Different, overlapping mechanisms may be responsible for the initial 
rapid increase, and subsequent slow intensification of pulmonary artery pressures (Vejlstrup et 
al., 1997) in response to hypoxia, and delaying our measurements to 90-120 minutes may have 
yielded different results. However, at altitude, where subjects were hypoxic for 8-12 days, RIPC 
failed to elicit any changes in PASP indicating that time of measurement likely does not explain 
our lack of effect at sea level. At high altitude, all participants exhibited a moderate elevation in 
PASP that is comparable with other high altitude studies (Antezana et al., 1998). Based on 
reports of reduced measures of NO-bioavailability and increased production of endothelin-1 
(Sartori et al., 1999; Bailey et al., 2010), we speculate that RIPC may differentially affect those 
with exaggerated HPV responses who are susceptible to high altitude pulmonary edema, 
although this hypothesis has yet to be tested.  
 
RIPC and peripheral chemosensitivity 
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A novel finding of this study is that RIPC augments the HVR during chronic hypoxia (Figure 4). 
We did not attempt to investigate any mechanisms underlying changes caused by RIPC, although 
this finding broadly supports previous observations by Foster and colleagues (Foster et al., 2014) 
that RIPC improves oxygen saturation upon ascent to high altitude.  Sensitivity of the carotid 
body relies on the balance of numerous systemic factors, many of which vary significantly on a 
daily basis, leading to a large daily intra-individual variation in the hypoxic ventilatory response. 
Mechanisms underpinning the observed increase in chemosensitivity are purely speculative, but 
might involve  increased release of neurotransmitters such as 5-hydroxytryptamine, or a hypoxia-
inducible factor-1 aided improvement in oxygen sensing (Nurse, 2010; Prabhakar & Semenza, 
2016).  
Methodological considerations 
A large amount of uncertainty still exists over the nature and magnitude of the ischemic stimulus 
required to optimally elicit the desired protective benefits of RIPC. An emerging pattern seems 
to suggest that there may be a dose-response relationship, i.e. thigh occlusion is more effective 
than arm occlusion; dual thigh treatment is more effective than single thigh; and more ischemic 
repeats and more consecutive days of treatment have an additive effect compared to single 
sessions (Koch et al., 2014). Inevitably, caution must be exercised, since the goal of ischemic 
preconditioning is to deliver small, non-lethal bouts of ischemia to an area, rather than creating 
an actual ischemic injury in the distal tissue. If we had utilized a longer duration of ischemia, 
more repeats, or added consecutive days of treatment we may have observed different results; 
however, the aim of this study was to explore the efficacy of one simple session of RIPC, with 
the goal of offering a simple prophylactic treatment to those travelling to high altitude on short 
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notice, or a quick therapeutic and practical aid for those who may be experiencing signs of 
mountain sickness.  
With a treatment such as RIPC, it is difficult to deliver a true “sham” protocol, as it is impossible 
to blind a subject to the obvious physical sensations associated with cuffs being inflated to 225 
mmHg over the thighs. For this reason, naïve subjects were verbally informed that the aim of the 
study was to explore differences between arterial (200mmHg) and venous (20mmHg) occlusion 
during their respective trials. 
We also acknowledge that the lack of an equally-weighted control group in the high altitude arm; 
however, with limited time and a small participant pool afforded to the study, we were only able 
to use four subjects to act as a time control. The most significant changes in acclimatization 
status occur within the first few days of arrival to high altitude (Swenson & Bärtsch, 2014), and 
we observed no changes in ventilation or any other physiological parameters in our time control 
group, suggesting that any acclimatization occurring between days 8-12 over the course of the 
study had little effect on our findings. 
Given the small sample size and lack of a repeated-measures control, these data must be 
interpreted judiciously and considered more exploratory than confirmatory.  For example, power 
calculations indicate that a much larger sample size (n>250) would have been needed to observe 
significant changes (>1%) in FMD with a power of 0.8. However, this is not feasible in high 
altitude research and supports the negligible influence of RIPC on FMD in hypoxia.  
Conclusions 
Our preliminary results indicate that one session of 4x5 minute dual-thigh RIPC treatment seems 
to have no benefit in terms of pulmonary vascular protection or preserving peripheral endothelial 
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function during acute and chronic hypoxia. Continued exploration of potential protective benefits 
that may be derived from utilizing different RIPC treatment strategies may be useful. An 
improved HVR 24 hour after preconditioning during chronic hypoxia suggests that RIPC can 
influence the hypoxic chemosensitivity of the carotid body. The HVR has been positively related 
to exercise performance at high (<6100 m) altitudes (Schoene et al., 1984) however, since 
resting SpO2 was unchanged, and an enhanced peripheral chemosensitivity may augment 
periodic breathing at altitude [reviewed in: (Ainslie et al., 2013)]- whether these changes are of 
advantage seems unlikely.  
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FIGURES: 
Figure 1. Schematic of the experimental protocol for Part 1 of the study representing acute 
hypoxia, performed near sea level (Kelowna, 344m). PASP = pulmonary artery systolic pressure 
measurement; FMD = flow-mediated dilation measurement, QICA=blood flow through the 
internal carotid artery; HVR = period of assessment of the hypoxic ventilatory response. 
 
Figure 2. Schematic of the experimental protocol for Part 2 of the study, during hypoxia. 
Performed at Barcroft Station after 8-12 days at high altitude (White Mountain, 3800m). PASP = 
time of pulmonary artery systolic pressure measurement; FMD = time of flow-mediated dilation 
measurement, QICA= time of measurement of blood flow through the internal carotid artery; 
HVR = period of assessment of the hypoxic ventilatory response. 
 
Figure 3: Acute Hypoxia.  Selected vascular and respiratory responses to hypoxia at baseline, 
and 1 hour, 24 hours, and 48 hours after dual-thigh RIPC. A) Absolute increase in pulmonary 
artery systolic pressure (PASP) from normoxia to 30 minutes of hypoxia. B) Change in brachial 
artery flow-mediated dilation (FMD) response from normoxia to hypoxia (i.e. normoxia % - 
hypoxia %)  C) Peak flow-reactivity of the internal carotid artery (ICA) upon the transition from 
normoxia to hypoxia. D) The hypoxic ventilatory response (HVR). Black bars represent means 
for RIPC, grey bars represent means for Sham. End-tidal partial pressure of O₂ was clamped at 
50 mmHg under isocapnic conditions in the hypoxia phase. Testing was to model acute hypoxia, 
performed at low-altitude (344m). Individual data points are shown, bars represent group means. 
A 2x4 ANOVA (factors: time, treatment) was used to identify significant differences, P>0.05 for 
all interactions.  
 
Figure 4. Chronic hypoxia. Selected vascular and respiratory parameters at baseline, and 1 
hour, 24 hours, and 48 hours after dual-thigh RIPC or time control, after 8-12 days at high 
altitude (3800m). A) Pulmonary artery systolic pressure (PASP),  B) Flow-mediated dilation 
(FMD) of the brachial artery, C) Peak hypoxic flow-reactivity of the internal carotid artery 
(ICA),  D) The hypoxic ventilatory response (HVR). Black bars represent means for RIPC, grey 
bars represent means for Time control. For C) & D), end-tidal partial pressure of O₂ was 
clamped to 45 mmHg under isocapnic conditions in the hypoxia phase. Individual data points are 
shown, bars represent group means. ANOVA was used to determine the effect of time for each 
condition. *P-value represents difference from baseline.  
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Table 1.  Study subject characteristics 
  
  Acute Hypoxia   Chronic Hypoxia 
Condition RIPC Sham   RIPC Time Control 
N (females) 8 (3) 8 (3)   8 (3) 4 (0) 
Age (years) 24.1±3.6 24.7±3.7   23.9±3.4 27.5±2.9 
Weight (kg) 69.1±6.2 71.3±9.6   70.4±9.9 74.75±10.2 
Height (cm) 173.3±6.2 175.7±4.6   177.1±5.4 175.0±2.2 
There were no differences in subject demographics (age, height, weight) 
between treatment conditions or between  acute and chronic hypoxia branches 
of the study (P>0.05). 
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Table 2. Acute Hypoxia       
   RIPC  Sham 
  
BL 1 hour 24 hours 48 hours 
 
BL 1 hour 24 hours 48 hours 
FMD (%) normoxia 7.74±3.0 7.90±2.7 6.78±2.3 7.16±2.2  7.90±2.7 8.15±2.8 8.05±2.9 6.92±2.4 
 hypoxia 7.24±2.9 7.34±2.3 6.24±2.8 6.77±3.4  7.45±3.0 7.47±2.3 7.36±2.8 6.56±2.8 
  Time: P = 0.652, O₂: P=0.235, Interaction P=0.856 
 
Time: P = 0.623, O₂: P=0.187, Interaction P=0.995 
           
PASP (mmHg) normoxia 22.3±3.6 21.9±3.2 21.7±4.9 21.1±2.5 
 
22.53±2.1 23.00±2. 2 23.4±2.46 22.7±2.71 
 hypoxia 25.2±3.9 25.3±3.4 24.5±5.0 24.1±4.9 
 
26.1±2.1 25.8±3.0 28.9±3.2 26.4±2.6 
  
Time: P = 0.999, O₂: P=0.009, Interaction P=0.993 
 
Time: P = 0.652, O₂: P<0.001, Interaction P=0.991 
           
ICA flow (mL/min) normoxia 242.7±30.2 232.5±38.3 237.8±42.2 235.9±32.8 
 
230.6±31.0 231.8±23.3 220.8±32.8 213.3±82.8 
 
hypoxia 286.1±42.1 282.6±41.9 277.4±67.8 276.2±54.2 
 
294.4±6 293.7±46 275.8±41 249.9±98 
  
Time: P = 0.325, O₂: P=0.003, Interaction P=0.561 
 
Time: P = 0.767, O₂: P<0.001, Interaction P=0.880 
        
MCAv (cm/s) normoxia 56.6±3.6 54.7±3.1 55.9±5.9 56.8±6.5  58.4±14.7 61.2±12.9 57.2±9.8 57.5±10.3 
 hypoxia 65.3±7.5 65.2±5.9 63.3±4.4 62.4±9.5  67.3±16.0 68.0±15.7 67.1±10.1 62.7±12.1 
  Time: P = 0.877, O₂: P<0.001, Interaction P=0.924  Time: P = 0.430, O₂: P<0.001, Interaction P=0.343 
           
HR (bpm) normoxia 66.0±18.6 66.2±16.0 64.1±12.5 63.8±11.8  63.9±12.7 68.1±13.3 64.1±12.7 64.0±14.0 
 hypoxia 71.5±11.8 71.8±14.4 71.5±12.3 70.4±10.4  75.7±18.4 77.9±16.4 72.9±14.5 76.1±9.7 
  Time: P = 0.949, O₂: P<0.001, Interaction P=0.909  Time: P = 0.899, O₂: P<0.001, Interaction: P=0.906 
           
MAP (mmHg) normoxia 89.9±8.4 92.2±13.7 93.4±17.9 87.2±7.3  85.1±8.3 86.4±7.0 84.8±7.0 82.5±10.8 
 hypoxia 89.9±14.4 93.0±13.4 88.0±13.7 86.3±9.7  88.3±7.2 86.4±10.9 85.1±10.6 89.2±7.3 
  Time: P = 0.342, O₂: P=0.312, Interaction P=0.505  Time: P = 0.945, O₂: P=0.421, Interaction: P=0.790 
           
VE (l/min) normoxia 11.5±2.6 11.9±1.8 11.3±1.8 11.4±1.3  11.4±2.6 12.6±2.4 11.4±1.1 11.1±2.5 
 hypoxia 20.7±4.9 20.9±5.5 20.0±3.7 21.0±6.6  19.6±5.9 18.4±4.4 19.1±4.7 19.3±4.6 
  Time: P = 0.577, O₂: P<0.001, Interaction P=0.514  Time: P = 0.889, O₂: P<0.001, Interaction: P=.631 
           
PETCO₂ (mmHg) normoxia 40.7±3.0 39.3±3.3 40.7±2.7 41.0±2.8  40.3±1.6 40.5±2.6 40.5±0.8 41.2±2.3 
 hypoxia 41.7±2.3 40.6±3.0 40.2±2.6 41.3±2.3  41.6±2.9 41.0±2.5 41.5±3.0 41.7±2.4 
  Time: P = 0.798, O₂: P=0.342, Interaction P=0.956  Time: P = 0.821, O₂: P=0.344, Interaction: P=0.999 
           
PETO₂ (mmHg) normoxia 95.9±4.3 96.5±3.3 95.5±5.2 94.9±7.1  99.3±3.9 100.1±5.2 99.4±3.4 98.7±4.8 
 Remote Ischemic Preconditioning and Vascular Function in Hypoxia 
 
 hypoxia 49.8±1.6 50.0±1.2 50.3±1.9 50.4±1.7  49.8±0.9 49.9±1.3 50.1±1.5 49.4±0.8 
  Time: P = 0.879, O₂: P<0.001, Interaction P=0.853  Time: P = 0.967, O₂: P<0.001, Interaction: P=0.999 
      SPO₂ (%) normoxia 98.4±1.0 97.9±1.2 97.9±1.0 97.3±1.4  98.1±1.2 98.2±0.9 97.5±1.4 97.7±1.3 
 
  
hypoxia 82.6±3.6 83.0±4.1 83.0±4.2 83.1±3.6  80.5±3.7 79.7±4.3 80.0±3.8 81.0±3.4 
 
   
Time: P = 0.999, O₂: P<0.001, Interaction P=0.843  Time: P = 0.899, O₂: P<0.001, Interaction: P=0.976 
 
Acute hypoxia. Selected cardiovascular and respiratory parameters at baseline, and 1 hour, 24 hours, and 48 hours after dual-thigh RIPC, during room-air 
breathing and acute hypoxia. End-tidal partial pressure of O₂ was clamped to 50 mmHg under isocapnic conditions in the hypoxia phase. Testing was 
performed at low-altitude (344m). Data represents group means ± SD. A 2-way ANOVA was used to evaluate statistical differences in each group. 
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 Table 3. Chronic Hypoxia 
         
 
RIPC 
  
Time control 
 
 Baseline 1 hour 24 hours 48 hours P-value  Baseline 1 hour 24 hours 48 hours P-value 
Room Air (3800m)           
HR (bpm) 67.4±11.3 68.2±14.0 67.0±13.1 66.4±10.3 0.53  59.3±18.8 58.0±16.0 60.1±16.3 59.9±12.9 0.35 
MAP (mmHg) 95.2±4.6 90.5±10.3 93.8±8.2 93.6±6.2 0.63  92.5±6.5 98.7±6.9 89.7±12.6 94.2±10.8 0.77 
SPO₂  (%) 90.2±2.1 89.6±1.4 89.2±1.1 89.3±1.9 0.59  87.5±4.1 90.3±3.0 88.8±2.0 89.5±0.6 0.6 
VE (l/min) 10.8±3.9 13.8±2.7 14.1±1.4 13.6±1.4 0.22  12.1±1.4 12.8±0.9 13.0±0.5 13.1±1.5 0.55 
PETO₂ (mmHg) 59.5±2.8 59.0±1.9 58.7±2.7 58.4±1.5 0.32  53.6±2.9 55.9±4.4 55.0±3.0 55.7±0.6 0.31 
PETCO₂ (mmHg) 28.1±1.8 27.9±1.6 28.4±1.9 28.4±1.9 0.93  30.8±1.9 30.0±2.2 30.9±1.9 30.6±0.6 0.52 
MCAv (cm/s) 52.7±11.6 53.7±10.7 51.4±8.8 54.1±10.2 0.64  61.7±4.0 62.5±4.2 62.8±6.8 58.4±7.9 0.41 
ICA flow (mL/s) 227.0±46.7 246.8±34.2 248.1±25.2 238.9±25.6 0.31  262.0±27.0 290.3±31.7 262.0±47.0 521.0±28.4 0.62 
            
Isocapnic Hypoxia (PETO₂ = 45mmHg)         
HR (bpm) 73.1±11.7 74.4±13.6 72.8±14.9 72.9±13.2 0.31  61.5±17.7 62.2±17.8 66.4±19.2 67.9±17.9 0.47 
MAP (mmHg) 102.3±8.2 99.5±10.4 102.5±7.8 99.3±9.3 0.6  96.7±1.4 96.2±12.6 89.7±4.0 97.8±15.3 0.32 
SPO₂ (%) 78.0±2.0 78.6±2.9 78.2±3.2 79.0±2.2 0.54  79.5±3.2 80.2±0.5 80.0±1.75 78.9±1.9 0.85 
MCAv (cm/s) 61.5±12.0 59.6±13.5 58.8±11.2 61.3±10.9 0.71  66.1±3.3 66.7±7.1 65.5±10.8 67.0±5.6 0.64 
ICA flow 
(mL/min) 
296.5±26.0 308.2±37.4 291.1±23.3 297.0±38.2 0.73 
 
296.6±29.1 302.3±52.0 350.2±25.5 334.4±38.6 0.88 
VE peak (L/min) 29.2±16.7 37.2±15.0 42.6±11.1* 40.7±15.2 0.02  32.7±15.4 30.9±10.6 36.4±18.2 37.6±11.3 0.51 
VE average 
(L/min) 
18.2±9.0 23.8±6.1 28.9±8.3* 25.7±11.7 0.04 
 
25.5±11.0 24.0±12.8 25.8±7.6 30.6±6.4 0.48 
 
Selected vascular and respiratory parameters at baseline, and 1 hour, 24 hours, and 48 hours after dual-thigh RIPC or time control, after 8-12 days at high 
altitude (3800m). End-tidal partial pressure of O₂ was clamped to 45 mmHg under isocapnic conditions in the hypoxia phase. P-value represents between-
groups significance. * represents difference from baseline (P<0.05). 
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